Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

Naveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Megan Dupuis, Lisa Zhou, Sherry Pierce, Keyur P. Patel, Lucia Masarova, Jorge Cortes, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

It is well known that patients with cancer may subsequently develop secondary/therapy-related neoplasms, generally exhibiting poorer prognosis than their de novo counterparts.1 Among patients with myeloproliferative neoplasms (MPN), there may be a higher rate of second malignancies before, concomitant with, or after their MPN diagnosis as compared with the general population2-9 (Table 1). We recently reported (and others confirmed) the association of lymphoid malignancies coexistent with an MPN diagnosis and found this to be an overall rare phenomenon that did not predict for worse clinical outcomes among MPN patients.10 The incidence and relative risk of post-MPN lymphoid neoplasms has been evaluated, and a 1.4- to 5-fold higher risk in this population has been identified, regardless of therapy received (Table 1). A recent important report in this area raises the possibility that those patients with MPN treated with a Janus kinase (JAK) inhibitor class of therapies may have a markedly higher rate of development of a subsequent lymphoma than patients who did not receive these therapies.11 Given the paucity of data sets that specifically focus on those patients with MPN treated with a JAK inhibitor subsequently diagnosed with a lymphoma, we sought to determine the characteristics and outcomes of this particular subset of patients in our large patient database.

Original languageEnglish (US)
Pages (from-to)2348-2351
Number of pages4
JournalBlood
Volume133
Issue number21
DOIs
StatePublished - May 23 2019
Externally publishedYes

Fingerprint

Janus Kinases
Lymphoma
Neoplasms
Therapeutics
Second Primary Neoplasms
Databases

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Pemmaraju, N., Kantarjian, H., Nastoupil, L., Dupuis, M., Zhou, L., Pierce, S., ... Verstovsek, S. (2019). Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood, 133(21), 2348-2351. https://doi.org/10.1182/blood-2019-01-897637

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. / Pemmaraju, Naveen; Kantarjian, Hagop; Nastoupil, Loretta; Dupuis, Megan; Zhou, Lisa; Pierce, Sherry; Patel, Keyur P.; Masarova, Lucia; Cortes, Jorge; Verstovsek, Srdan.

In: Blood, Vol. 133, No. 21, 23.05.2019, p. 2348-2351.

Research output: Contribution to journalArticle

Pemmaraju, N, Kantarjian, H, Nastoupil, L, Dupuis, M, Zhou, L, Pierce, S, Patel, KP, Masarova, L, Cortes, J & Verstovsek, S 2019, 'Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy', Blood, vol. 133, no. 21, pp. 2348-2351. https://doi.org/10.1182/blood-2019-01-897637
Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S et al. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019 May 23;133(21):2348-2351. https://doi.org/10.1182/blood-2019-01-897637
Pemmaraju, Naveen ; Kantarjian, Hagop ; Nastoupil, Loretta ; Dupuis, Megan ; Zhou, Lisa ; Pierce, Sherry ; Patel, Keyur P. ; Masarova, Lucia ; Cortes, Jorge ; Verstovsek, Srdan. / Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. In: Blood. 2019 ; Vol. 133, No. 21. pp. 2348-2351.
@article{de46ff3ff0d9462582241c59b7dc05e8,
title = "Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy",
abstract = "It is well known that patients with cancer may subsequently develop secondary/therapy-related neoplasms, generally exhibiting poorer prognosis than their de novo counterparts.1 Among patients with myeloproliferative neoplasms (MPN), there may be a higher rate of second malignancies before, concomitant with, or after their MPN diagnosis as compared with the general population2-9 (Table 1). We recently reported (and others confirmed) the association of lymphoid malignancies coexistent with an MPN diagnosis and found this to be an overall rare phenomenon that did not predict for worse clinical outcomes among MPN patients.10 The incidence and relative risk of post-MPN lymphoid neoplasms has been evaluated, and a 1.4- to 5-fold higher risk in this population has been identified, regardless of therapy received (Table 1). A recent important report in this area raises the possibility that those patients with MPN treated with a Janus kinase (JAK) inhibitor class of therapies may have a markedly higher rate of development of a subsequent lymphoma than patients who did not receive these therapies.11 Given the paucity of data sets that specifically focus on those patients with MPN treated with a JAK inhibitor subsequently diagnosed with a lymphoma, we sought to determine the characteristics and outcomes of this particular subset of patients in our large patient database.",
author = "Naveen Pemmaraju and Hagop Kantarjian and Loretta Nastoupil and Megan Dupuis and Lisa Zhou and Sherry Pierce and Patel, {Keyur P.} and Lucia Masarova and Jorge Cortes and Srdan Verstovsek",
year = "2019",
month = "5",
day = "23",
doi = "10.1182/blood-2019-01-897637",
language = "English (US)",
volume = "133",
pages = "2348--2351",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "21",

}

TY - JOUR

T1 - Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

AU - Pemmaraju, Naveen

AU - Kantarjian, Hagop

AU - Nastoupil, Loretta

AU - Dupuis, Megan

AU - Zhou, Lisa

AU - Pierce, Sherry

AU - Patel, Keyur P.

AU - Masarova, Lucia

AU - Cortes, Jorge

AU - Verstovsek, Srdan

PY - 2019/5/23

Y1 - 2019/5/23

N2 - It is well known that patients with cancer may subsequently develop secondary/therapy-related neoplasms, generally exhibiting poorer prognosis than their de novo counterparts.1 Among patients with myeloproliferative neoplasms (MPN), there may be a higher rate of second malignancies before, concomitant with, or after their MPN diagnosis as compared with the general population2-9 (Table 1). We recently reported (and others confirmed) the association of lymphoid malignancies coexistent with an MPN diagnosis and found this to be an overall rare phenomenon that did not predict for worse clinical outcomes among MPN patients.10 The incidence and relative risk of post-MPN lymphoid neoplasms has been evaluated, and a 1.4- to 5-fold higher risk in this population has been identified, regardless of therapy received (Table 1). A recent important report in this area raises the possibility that those patients with MPN treated with a Janus kinase (JAK) inhibitor class of therapies may have a markedly higher rate of development of a subsequent lymphoma than patients who did not receive these therapies.11 Given the paucity of data sets that specifically focus on those patients with MPN treated with a JAK inhibitor subsequently diagnosed with a lymphoma, we sought to determine the characteristics and outcomes of this particular subset of patients in our large patient database.

AB - It is well known that patients with cancer may subsequently develop secondary/therapy-related neoplasms, generally exhibiting poorer prognosis than their de novo counterparts.1 Among patients with myeloproliferative neoplasms (MPN), there may be a higher rate of second malignancies before, concomitant with, or after their MPN diagnosis as compared with the general population2-9 (Table 1). We recently reported (and others confirmed) the association of lymphoid malignancies coexistent with an MPN diagnosis and found this to be an overall rare phenomenon that did not predict for worse clinical outcomes among MPN patients.10 The incidence and relative risk of post-MPN lymphoid neoplasms has been evaluated, and a 1.4- to 5-fold higher risk in this population has been identified, regardless of therapy received (Table 1). A recent important report in this area raises the possibility that those patients with MPN treated with a Janus kinase (JAK) inhibitor class of therapies may have a markedly higher rate of development of a subsequent lymphoma than patients who did not receive these therapies.11 Given the paucity of data sets that specifically focus on those patients with MPN treated with a JAK inhibitor subsequently diagnosed with a lymphoma, we sought to determine the characteristics and outcomes of this particular subset of patients in our large patient database.

UR - http://www.scopus.com/inward/record.url?scp=85065254485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065254485&partnerID=8YFLogxK

U2 - 10.1182/blood-2019-01-897637

DO - 10.1182/blood-2019-01-897637

M3 - Article

C2 - 30796023

AN - SCOPUS:85065254485

VL - 133

SP - 2348

EP - 2351

JO - Blood

JF - Blood

SN - 0006-4971

IS - 21

ER -